W. Charles Newhall's Insider Trades & SAST Disclosures
W. Charles Newhall's most recent trade in Supernus Pharmaceuticals Inc was a trade of 5,369 Restricted Stock Units done . Disclosure was reported to the exchange on Feb. 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern W. Charles Newhall.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2025 | 5,369 | 0 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2025 | 5,369 | 135,644 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 7,296 | 7,296 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 4,475 | 4,475 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 20,000 | 0 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.13 per share. | 11 Nov 2024 | 20,000 | 140,975 (0%) | 0% | 9.1 | 182,600 | Common Stock |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Sale of securities on an exchange or to another person at price $ 36.24 per share. | 11 Nov 2024 | 10,700 | 130,275 (0%) | 0% | 36.2 | 387,768 | Common Stock |
| Supernus Pharmaceuticals Inc | Charles Newhall W. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,886 | 120,975 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | W. Charles Newhall | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Feb 2024 | 3,886 | 0 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | W. Charles Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 8,252 | 8,252 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | W. Charles Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 5,369 | 5,369 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 6,293 | 6,293 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 3,886 | 3,886 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 3,882 | 112,132 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2023 | 3,882 | 0 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 2,203 | 108,250 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2022 | 8,722 | 0 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.90 per share. | 28 Dec 2022 | 8,722 | 110,453 (0%) | 0% | 7.9 | 68,904 | Common Stock |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 6,847 | 6,847 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 3,882 | 3,882 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Feb 2022 | 4,222 | 0 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2022 | 4,222 | 101,731 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 7,365 | 7,365 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Charles W. Newhall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 4,222 | 4,222 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges